NetScientific (NSCI)

Sector:

Financials

 104.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 180.00p
  • 52 Week Low: 43.00p
  • Currency: UK Pounds
  • Shares Issued: 20.98m
  • Volume: 0
  • Market Cap: £21.81m
  • RiskGrade: 410
  • Beta: 1.38

NetScientific subsidiary strikes exclusive licensing deal with AstraZeneca

By Josh White

Date: Monday 07 Jun 2021

LONDON (ShareCast) - (Sharecast News) - Life sciences investment company NetScientific announced on Monday that its subsidiary ProAxsis has entered into an exclusive licensing agreement with AstraZeneca.
The AIM-traded firm said ProAxsis would take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 - the virus responsible for the Covid-19 disease - serology enzyme-linked immunosorbent assay (ELISA) developed by an internal research team at AstraZeneca.

In return for providing access to the required intellectual property and technical know-how, AstraZeneca would receive a royalty fee on future global net sales of the assay.

NetScientific holds 95% of ProAxsis on a fully-diluted basis.

"We're excited to be involved with this assay to support such a key area of global healthcare need," said ProAxsis chief executive officer Dr David Ribeiro.

"The research team at AstraZeneca have already completed significant optimisation and validation work, which has demonstrated the assay's high potential sensitivity and specificity of detecting SARS-CoV-2 antibodies.

"ProAxsis will extend this work to support the identification of people who have raised antibodies against this challenging virus."

John Clarkson, chairman of both Netscientific and ProAxsis, added that expanding the product portfolio and customer service offering were stated goals for ProAxsis, so both companies were "delighted" with the continued progress and reaching the "mutually-beneficial" agreement with AstraZeneca.

"Following the huge impact of the coronavirus pandemic on society, it's excellent news that we can play our part in the Covid-19 response and help deliver real benefits to the community, through the application of ProAxsis' expertise in respiratory assays."

Ruth March, senior vice-president of precision medicine at AstraZeneca, said the development of the serology ELISA was an example of AstraZeneca's "comprehensive response" to the Covid-19 pandemic.

"This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations."

At 0921 BST, shares in NetScientific were up 23.6% at 92.7p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

NetScientific Market Data

Currency UK Pounds
Share Price 104.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 180.00p
52 Week Low 43.00p
Volume 0
Shares Issued 20.98m
Market Cap £21.81m
Beta 1.38
RiskGrade 410

NetScientific Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.62% below the market average32.62% below the market average32.62% below the market average32.62% below the market average32.62% below the market average
34.38% below the sector average34.38% below the sector average34.38% below the sector average34.38% below the sector average34.38% below the sector average
Price Trend
39.92% above the market average39.92% above the market average39.92% above the market average39.92% above the market average39.92% above the market average
40.15% above the sector average40.15% above the sector average40.15% above the sector average40.15% above the sector average40.15% above the sector average
Income Not Available
Growth
23.89% above the market average23.89% above the market average23.89% above the market average23.89% above the market average23.89% above the market average
23.33% above the sector average23.33% above the sector average23.33% above the sector average23.33% above the sector average23.33% above the sector average

NetScientific Dividends

No dividends found

Trades for --2021

Time Volume / Share Price
0 @ 0.000p

NetScientific Key Personnel

CEO Ilian Iliev
CFO Stephen Crowe

Top of Page